<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37165712</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4598</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Muscle &amp; nerve</Title><ISOAbbreviation>Muscle Nerve</ISOAbbreviation></Journal><ArticleTitle>Hyperexcitability, neurodegeneration, and disease progression in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>103</StartPage><EndPage>105</EndPage><MedlinePgn>103-105</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mus.27843</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kiernan</LastName><ForeName>Matthew C</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0001-9054-026X</Identifier><AffiliationInfo><Affiliation>Bushell Professor of Neurology, Brain and Mind Centre, University of Sydney, Sydney, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Royal Prince Alfred Hospital, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Susanna B</ForeName><Initials>SB</Initials><Identifier Source="ORCID">0000-0003-0218-4707</Identifier><AffiliationInfo><Affiliation>School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Muscle Nerve</MedlineTA><NlmUniqueID>7803146</NlmUniqueID><ISSNLinking>0148-639X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Muscle Nerve. 2023 Aug;68(2):149-156</RefSource><PMID Version="1">36960740</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004576" MajorTopicYN="N">Electromyography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">hyperexcitability</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>11</Day><Hour>3</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37165712</ArticleId><ArticleId IdType="doi">10.1002/mus.27843</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Vucic S, Higashihara M, Sobue G, et al. ALS is a multistep process in South Korean, Japanese, and Australian patients. Neurology. 2020;94(15):e1657-e1663.</Citation></Reference><Reference><Citation>Kiernan MC, Vucic S, Talbot K, et al. Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nat Rev Neurol. 2021;17(2):104-118.</Citation></Reference><Reference><Citation>Shefner JM, Al-Chalabi A, Baker MR, et al. A proposal for new diagnostic criteria for ALS. Clin Neurophysiol. 2020;131(8):1975-1978.</Citation></Reference><Reference><Citation>Noto Y, Kataoji T, Watanabe K, Mizuno T. Assessment of motor unit firing by high-density surface electromyography detects motor neuronal hyperexcitable state in amyotrophic lateral sclerosis. Muscle Nerve. 2023;68:149-156.</Citation></Reference><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942-955.</Citation></Reference><Reference><Citation>Simon NG, Turner MR, Vucic S, et al. Quantifying disease progression in amyotrophic lateral sclerosis. Ann Neurol. 2014;76:643-657.</Citation></Reference><Reference><Citation>Heath PR, Shaw PJ. Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve. 2002;26(4):438-458.</Citation></Reference><Reference><Citation>Park SB, Vucic S, Kiernan MC. Axonal excitability in amyotrophic lateral sclerosis: axonal excitability in ALS. Neurotherapeutics. 2017;14:78-90.</Citation></Reference><Reference><Citation>Vucic S, Cheah BC, Kiernan MC. Dissecting the mechanisms underlying short-interval intracortical inhibition using exercise. Cereb Cortex. 2010;21(7):1639-1644.</Citation></Reference><Reference><Citation>Dharmadasa T, Howells J, Matamala JM, et al. Cortical inexcitability defines an adverse clinical profile in amyotrophic lateral sclerosis. Eur J Neurol. 2021;28:90-97.</Citation></Reference><Reference><Citation>Vucic S, Kiernan MC. Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. Brain. 2006;129(Pt 9):2436-2446.</Citation></Reference><Reference><Citation>Menon P, Kiernan MC, Vucic S. Cortical dysfunction underlies the development of the split-hand in amyotrophic lateral sclerosis. PLoS One. 2014;9:e87124.</Citation></Reference><Reference><Citation>Howells J, Sangari S, Matamala JM, Kiernan MC, Marchand-Pauvert V, Burke D. Interrogating interneuron function using threshold tracking of the H reflex in healthy subjects and patients with motor neurone disease. Clin Neurophysiol. 2020;31:1986-1996.</Citation></Reference><Reference><Citation>Eisen A, Braak H, Del Tredici K, et al. Cortical influences drive amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2017;88:917-924.</Citation></Reference><Reference><Citation>Tan RH, Kril JJ, Fatima M, et al. TDP-43 proteinopathies: pathological identification of brain regions differentiating clinical phenotypes. Brain. 2015;138(Pt 10):3110-3122.</Citation></Reference><Reference><Citation>Siklos L, Engelhardt J, Harati Y, Smith RG, Joo F, Appel SH. Ultrastructural evidence for altered calcium in motor nerve terminals in amyotropic lateral sclerosis. Ann Neurol. 1996;39:203-216.</Citation></Reference><Reference><Citation>Bensimon G, Lacomblez L, Meininger V, the ALS/ Riluzole Study Group. A controlled trial of riluzole in amyothropic lateral sclerosis. N Engl J Med. 1994;330:585-590.</Citation></Reference><Reference><Citation>Vucic S, Lin CS-Y, Cheah BC, et al. Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. Brain. 2013;136(5):1361-1370.</Citation></Reference><Reference><Citation>Wainger BJ, Macklin EA, Vucic S, et al. Effect of ezogabine on cortical and spinal motor neuron excitability in amyotrophic lateral sclerosis: a randomized clinical trial. JAMA Neurol. 2021;78:186-196.</Citation></Reference><Reference><Citation>Gunes ZI, Kan VW, Jiang S, Logunov E, Ye X, Liebscher S. Cortical hyperexcitability in the driver's seat in ALS. Clin Transl Neurosci. 2022;6:5. doi:10.3390/ctn6010005</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>